Abstract
Benign uterine leiomyoma (U.LMA) and malignant uterine leiomyosarcoma (U.LMS), which are both uterine mesenchymal tumors, are distinguished by the number of cells with mitotic activity. However, uterine mesenchymal tumors contain tumor cells with various cell morphologies; therefore, making a diagnosis, including differentiation between benign tumors and malignant tumors, is difficult. For example, A cotyledonoid dissecting leiomyoma is a uterine leiomyoma with a very rare placental lobed tissue morphology that can be misdiagnosed as a malignant uterine leiomyosarcoma because of its rarity and characteristic appearance on gross examination. Similar to the detection of a suspicious malignant mass during MRI imaging examination by medical staff, healthcare professionals must understand the characteristic appearance of a cotyledonoid dissecting leiomyoma. Clinicians and pathologists must understand the oncologic features of cotyledonoid dissecting leiomyoma to prevent misdiagnosis of malignancy and consequent overtreatment.
Reference17 articles.
1. Ye H, Qi X, Tian Y, Yang K, Zuo X, Peng Z. Case Report: Cotyledonoid Dissecting Leiomyoma in a 49-Year-Old Woman. Translational Cancer Research. 2022. Accepted on October 20, 2022.
2. Uterine leiomyoma. Female Genital Tumours WHO Classification of Tumours, 5th ed., Vol.4. WHO Classification of Tumours Editorial Board. WORLD HEALTH ORGANIZATION. 2020; pp272-276.
3. WHO classification of mesenchymal tumours of the lower genital tract. Female Genital Tumours WHO Classification of Tumours, 5th ed., Vol.4. WHO Classification of Tumours Editorial Board. WORLD HEALTH ORGANIZATION. 2020; pp13.
4. Zaloudek CJ, Hendrickson MR, Soslow RA. Mesenchymal tumors of the uterus. In Kurman R (ed): Blaustein’s Pathology of the Female Genital Tract, 6th ed. Springer, New York, 2010, pp453-527.
5. Intravenous leiomyotosis. Female Genital Tumours WHO Classification of Tumours, 5th ed., Vol.4. WHO Classification of Tumours Editorial Board. WORLD HEALTH ORGANIZATION. 2020; pp277-278.